TMM to another TMM to form TDM by Ag85 complex enzymes. The Ag85 complex is one of the promising targets for novel antimycobacterial drugs and vaccines. We present our recently developed high throughput screening (HTS) assays suitable for the identification of potential inhibitors against Ag85.
Discovery of the cord factor (Trehalose 6,6´-di-mycolate; TDM)
In 1884, Robert Koch described M. tuberculosis bacilli grown in culture as rope-like structures (Koch, 1884) . More than half a century later, in 1947 Middlebrook found that the ability to form cords under specific conditions is an "essential accompaniment of virulence" (Middlebrook et al., 1947) . In 1950 Bloch extracted the substance responsible for cord formation from virulent organisms and identified it as a "toxic substance" (Bloch, 1950) .
The removal of the substance with petroleum ether resulted in somehow avirulent organisms but did not affect the growth of the bacilli. This suggested that the substance was located at the surface and since it was obtained only from "cordforming" organisms it was called "cord factor" (Bloch, 1950; Middlebrook et al., 1947) . Six years later the cord factor was finally identified as trehalose 6,6´-di-mycolate (TDM) by Noll (Behling et al., 1993a; Noll, 1956) . TDM is the most abundant glycolipid produced by virulent M. tuberculosis (Hunter et al., 2006a) . TDM molecules consist of trehalose (TDM glycan-head). Trehalose is abundant in mycobacteria as a free component (Elbein & Mitchell, 1973; Elbein et al., 2003) . In the cord factor trehalose is esterified to two mycolic acid residues and the residues length is variable from species to species (Fig. 1) . Mycobacterial mycolic acids contain generally 20-80 carbons (Spargo et al., 1991) . The cord factor is comprised of trehalose which esterifed to two mycolic acid residues through their 6-and 6'-hydroxyl groups.
Effects of the cord factor on the immune system
TDM inhibits the process of phagosome-lysosome fusion and is thus a key compound for the survival of the bacillus inside the host´s phagosomes (Indrigo et al., 2002) . TDM induces a broad range of cytokine secretion in the host´s immune system, especially production of IL-1 , IL-6, and TNF in macrophages (Matsunaga & Moody, 2009 ). In the recent years it has been shown that TDM is a key driver of secondary and cavitary disease type of tuberculosis (Hunter et al., 2006b) . Despite the various severe effects on the host immune system the host receptor could not been identified. In 2009 Ishikawa et al. could demonstrate that macrophage inducible C-type lectin (Mincle) is an essential receptor for TDM (Ishikawa et al., 2009 ).
TDM as vaccine adjuvant
In the last years TDM has been used intensively as immunomodulatory and vaccine adjuvant (Behling et al., 1993b; Noll, 1956) . TDM can reproduce several pathophysiologic properties of M. tuberculosis infection including granuloma formation and induction of proinflammatory cytokines, such as IL-1 , IL-6, and TNF in macrophages (Matsunaga & Moody, 2009 ). TNF (cachexin) has several toxic effects on host physiology, including sepsis, fever syndromes and cachexia (Silva & Faccioli, 1988) .
Doses as little as 1-5 µg are granulomagenic in the lungs of mice (Bekierkunst et al., 1969) . Moreover TDM increases the production of antibodies (Behling et al., 1993b; Perez et al., 1994; Perez et al., 2000) and it up-regulates the expression of MHCII on macrophages (Ryll et al., 2001) . TDM also induces in vivo production of IL-12 (Oswald et al., 1997) . Injected as mineral oil solution (Silva & Faccioli, 1988 ) TDM forms monolayers, where the mycolic acids are exposed. In the monolayer form TDM is highly toxic (lethal dose in mice: LD 50 ~30 μg) and kills macrophages in minutes (Hunter et al., 2006b) . In aqueous suspension TDM forms micelles, where the mycolic acid groups are completely covered and TDM is non-toxic (lethal dose in mice: LD 50 >50,000 μg). Micellar TDM prevents phagosome/lysosome fusion and thus promotes the survival of mycobacteria in the macrophage. Nevertheless, until now there is no experimental evidence for the existence or formation of TDM micelles or monolayers in vivo. Due to its strong immunstimulatory effect, several studies have used TDM as a potential adjuvant in different vaccination models. In 1976 Saito et al. were the first who described the cord factor as good adjuvant in mice and rats but with only low adjuvant effect in guinea pigs (Saito et al., 1976) . Lima et al. could show that microspheres, containing TDM with a Hsp65-encoding DNA plasmid, were able to protect vaccinated mice against virulent M. tuberculosis (Lima et al., 2003) and against Leishmania major infection (Coelho et al., 2006) . The major problem using TDM as adjuvant is the relatively high toxicity of the mycolic acids and the accompanying contaminants during the preparation of TDM. A synthetic analog of the cord factor, trehalose-6,6-dibehenate (TDB), was shown to be an effective and safe alternative (Davidsen et al., 2005) . TDB is less toxic compared with TDM and easier to produce, making it a potent candidate in the field of vaccine development.
Drug targets in the biosynthesis of the cord factor
The cord factor (trehalose 6,6´-di-mycolate) is composed of a sugar and a mycolic acid component. In the following section we present the trehalose and mycolic acid biosynthesis steps and the target enzymes in their biochemical context. Especially enzymes of mycolic acid biosynthesis, such as methyl transferase (PcaA) (Glickman et al., 2000) , ß-ketoacyl-acyl carrier protein synthase (KasAB and FabH) (Bhatt et al., 2007) , acyl-AMP ligase (Fad32) (Portevin et al., 2005) and polyketide synthase (Psk13) (Portevin et al., 2004) , are regarded as promising targets for anti-TB drug development.
Biosynthesis of trehalose
Mycobacteria possess three pathways for trehalose synthesis (Kaur et al., 2009) . Trehalose can by synthesized from glucose-6-phosphate catalyzed by trehalose-6-phosphate synthase (OtsA, Rv3490) (Pan et al., 2002) and trehalose-6-phosphate phosphatase (OtsB2, Rv3372) (Pan et al., 2002) . The second pathway generates trehalose from glycogen involving the maltooligosyltrehalose synthase (TreY, Rv1653c) and the maltooligosyltrehalose trehalohydrolase (TreZ, Rv1562c). In the third pathway maltose is converted to trehalose by the trehalose synthase (TreS, Rv0126) . While all the three pathways are functional and essential for the proliferation of M. smegmatis (Woodruff et al., 2004) , the OtsAB pathway is predominant and strictly essential in M. tuberculosis (Fig. 2 ). In the genome sequence of M. tuberculosis exist two otsB homologues, but only OtsB2 (Rv3372) has a functional role in the pathway. OtsB2 has been suggested as an attractive target for novel drugs due to absence of trehalose in mammalian cell (Murphy et al., 2005) .
Trehalose transporters
The LpqY-SugA-SugB-SugCATP-binding cassette transporter is highly specific for uptake of the disaccharide trehalose. Since trehalose is not present in mammals, it is unlikely that this system is used for sugar acquisition from the host. Trehalose release is known to occur as a byproduct of the biosynthesis of the mycolic acid cell envelope by M. tuberculosis antigen 85 complex. The mycolyltransferases of the antigen 85 complex transfer the lipid moiety of the glycolipid trehalose monomycolate (TMM) to arabinogalactan or another molecule of TMM, yielding trehalose dimycolate. These reactions lead to a constant release of trehalose from the cell. The LpqY-SugA-SugB-SugC ATP-binding cassette has been suggested as transporter system (Fig. 2) , recycling the released trehalose. Perturbations in trehalose recycling strongly impaired virulence of M. tuberculosis. (Kalscheuer et al., 2010) . These sugar transporters are thought to play an important role in bacterial pathogenesis and have been suggested as target for tuberculosis chemotherapy (Kalscheuer et al., 2010) . 
Mycolic acid biosynthesis
Mycolic acids are -hydroxy fatty acids with a long -alkyl side chain. They are homologous series of fatty acids differing by a two-carbon unit (Asselineau & Lederer, 1950) . The mycolic acids are composed of an  branch at the alpha position in respect to the carboxylic group and a meromycolate branch. The "short"  branch contains species dependent 20-26 saturated carbon atoms. The "long" meromycolate branch has 50-60 carbon atoms and its chemical composition is highly variable, containing cyclopropyl or unsaturated bonds (mycolates), methoxy (methoxymycolates) and keto (ketomycolates) groups (Alahari et al., 2007) . The confusing denotation " -mycolates" refers not to their position in the molecule but to their position on thin layer chromatography. The "-mycolates" (cis, cisdicyclopropyl fatty acids) are the most abundant mycolic acids in M. tuberculosis (~57%), followed by methoxymycolates (32%) and ketomycolates (11%). The methoxy-and ketomycolates can have either the cis or trans configuration on the proximal cyclopropane ring. In summary there are five main classes of mycolic acids in M. tuberculosis (Schroeder et al., 2002; Takayama et al., 2005) .
In M. tuberculosis mycolic acids are essentially provided via conventional fatty acid biosynthesis. Mycobacteria contain both type I and type II FAS fatty acid biosynthesis systems. Fatty acid biosynthesis is initiated by the multifunctional FAS I enzyme (Rv2524c), catalyzing the de novo synthesis of long-chain acyl-CoAs (C16:0 and C18:0) from acetyl-CoA and using malonyl-CoA as an extender unit. The domains of the FAS-I multienzymecomplex are organized in the following order: acyltransferase, enoyl reductase, dehydratase, malonyl/palmitoyl transferase, acyl carrier protein (ACP), -keto reductase, -ketoacyl synthase (Fernandes & Kolattukudy, 1996) . In M. tuberculosis the C16:0-and C18:0-S-ACP adducts, are converted either to the CoA derivatives or further elongated by FAS I to produce C26:0 (Kikuchi et al., 1992) . In mycobacteria the de novo fatty acid biosynthesis is exclusively carried out by FAS-I, whereas the FAS-II system performs only the elongation of the fatty acids, generated by FAS-I. The FAS I and FAS II systems are connected by a key condensing enzyme, the -ketoacyl ACP synthase III or FabH, which catalyzes a decarboxylative condensation of malonyl-ACP with the acyl-CoA (C16:0-C20:0) products of the FAS-I system (Fig. 3) . The resulting 3-ketoacyl-ACP product is reduced to an acyl-ACP (extended by two carbons) and shuffled into the FAS II cycle.
The ACP cycles the growing acyl chain between four enzymes MabA (ketoacyl reductase), -hydroxyacy dehydrase, InhA (enoyl reductase) and KasA/B (-ketoacyl synthase). M. tuberculosis contains two -ketoacyl synthases, KasA and KasB, which share 67% identity. KasA seems to be essential for growth, while KasB is not essential but produces longer carbon chains (Bhatt et al., 2005; Slayden & Barry, 2002; Swanson et al., 2009) . The deletion of KasB in M. tuberculosis leads to mycolic acids that are 2-6 carbons shorter in length and a defect in trans-cycloproponation of oxygenated mycolic acids. Phenotypically leads a deletion of KasB to a loss of acid-fastness (Bhatt et al., 2007) . The most potent inhibitor for mycolic acid biosynthesis is isoniazid (INH). INH is a prodrug which is converted to the isonicotinoyl radical by KatG. INH forms a covalent adduct with NAD. This INH-NAD adduct inhibits FAS-II enoyl-ACP reductase InhA, which in consequence leads to inhibition of mycolic acid biosynthesis, and ultimately to cell death (Mdluli et al., 1998; Takayama et al., 1972; 1975; Wilming & Johnsson, 1999) . In M. tuberculosis, the C26:0 fatty acids synthesized by FAS I will become the substrate of a dedicated acyl-CoA carboxylase (ACCase) to generate the -carboxy C26:0 fatty acid used as one of the substrate by the Pks 13 in the biosynthesis of mycolic acids (Gavalda et al., 2009 ). The last steps of the biosynthesis of mycolic acids are catalyzed by proteins encoded by the fadD32-pks13-accD4 cluster. Pks13 ultimately condenses the two loaded fatty acyl chains to produce -alkyl -ketoacids, the precursors of mycolic acids (Gavalda et al., 2009) . FadD32 has been shown essential for growth (Carroll et al., 2011) . Double bonds at specific sites on mycolic acid precursors are modified by the action of cyclopropane mycolic acid synthases (CMASs) such as MmaA1-A4, PcaA and CmaA2, which are S-adenosyl-methionine-dependent methyl transferases (Alahari et al., 2007) . The antitubercular drug, thiacetazone (TAC) and its chemical analogues acts on CMASs, inhibiting mycolic acid cyclopropanation (Alahari et al., 2007; Alahari et al., 2009 ). 
TMM biosynthesis
TDM is thought to be synthesized exclusively outside the cell and its precursor TMM is transported outside the cell. In addition TMM has to be exported from the cytoplasm, to prevent the degradation of TMM inside the cell by the ubiquitously present Ag85/Fbp (Kilburn et al., 1982; Sathyamoorthy & Takayama, 1987) . The mycolyl group is first transferred from mycolyl-S-Pks13 (mycolyl-S-PPB) to D-mannopyranosyl-1phosphoheptaprenol by a proposed cytoplasmic mycolyltransferase I to yield Myc-PL 6-O-mycolyl--D-mannopyranosyl -1-phosphoheptaprenol (Myc-PL) (Besra et al., 1994) . Myc-PL migrates to the inner surface of the cell membrane and docks next to an ABC transporter, with its hydrophobic heptaprenol tail. The mycolyl group is transferred to trehalose 6-phosphate by a proposed membrane-associated mycolyltransferase II to form TMMphosphate, and the phosphate group is removed by the membrane-associated trehalose 6-phosphate phosphatase, yielding TMM. TMM is transported outside the cell by the ABC transporter (Fig. 4 ). There should be virtually no accumulation of TMM in the cytoplasm (Takayama et al., 2005) . Fig. 4 . The proposed process of incorporation of newly synthesized mycolic acids into major cell wall components. The process starts inside the cell. Newly synthesized mycolic acids are transferred to man-P-heptaprenol to produce 6-O-mycolyl--D-mannopyranosyl-1phosphoheptaprenol (Myc-PL) and after that to trehalose 6-phosphate to yield TMM-P by the proposed membrane-associated mycolyltransferase II (reaction 1). TMM is produced by dephosphorylation of TMM-P by the membrane-bound TMM-P phosphatase (reaction 2). The transportation of TMM to the outside is catalyzed by a proposed ABC transporter cassette (TMM transporter) (reaction 3). Outside the cell the Ag85 complex catalyzes the transfer of mycolate to another TMM and arabinogalactan to yield TDM (reaction 4) or arabinogalactan-mycolate (reaction 5) (Takayama et al., 2005) .
TDM biosynthesis by Ag85
The antigen 85 complex is composed of Ag85A (FbpA), Ag85B (FbpB), and Ag85C (FbpC) as the predominant secreted proteins in M. tuberculosis. The corresponding genes are fbpA (Rv3804c), fbpB (Rv1886c), and fbpC (Rv0129c) (Belisle et al., 1997; Wiker & Harboe, 1992) . The 85 complex proteins share 68-80% sequence identity (Belisle et al., 1997; Ronning et al., 2004) . The mycolyltransferases of the antigen 85 complex are located outside the cell membrane and transfer the lipid moiety of the glycolipid trehalose monomycolate (TMM) to another molecule of TMM yielding trehalose dimycolate or to arabinogalactan to form cell wall arabinogalactan-mycolate ( Fig. 4) (Sanki et al., 2009a) .
There is also evidence, the Ag85 complex proteins bind to fibronectin and the fibronectinbinding property of the Ag85 complex is important for mycobacterium life cycle in the host and macrophages (Klegerman et al., 1994; Ronning et al., 2004) . The crystal structures of the three 30-32 kDa proteins (Ag85A, B and C) have been determined (Anderson et al., 2001; Ronning et al., 2004) . These proteins contain a carboxylesterase domain bearing the highlyconserved consensus sequence GXXSXXG. The interaction between Ag85 and fibronectin is mediated by the sequence homologous to residues 56-66 (FEEYYQSGLSV) of the recombinant M. tuberculosis Ag85C (Ronning et al., 2004) . Up to date, the question remains open why Mycobacterium tuberculosis has three antigen 85 enzymes sharing the similar sequence and substrate specificity (Daffe, 2000; Ronning et al., 2004) .
Ag85 complex members from M. tuberculosis belong to the / hydrolase superfamily and catalyze the hydrolysis of ester and amide bonds using a catalytic triad comprised of Ser126, Glu230 and His262 in Ag85A/B and Ser124, Glu228 and His260 in Ag85C. All three enzymes contain two carbohydrate binding sites. The active site carbohydrate binding pocket binds TMM to form a temporary mycolate ester with the catalytic serine. The second carbohydrate binding site binds the incoming trehalose monomycolate, which "swings over" to the active site to displace the mycolate from its serine ester (Anderson et al., 2001; Ronning et al., 2004) . The second trehalose binding site is separated from the acyl binding pocket by a bulky phenylalanine in Ag85A/B or a smaller leucine in Ag85C. All residues that form the active site carbohydrate binding pocket are 100% conserved in the M. tuberculosis antigen 85 proteins, while the surface of the acyl binding pocket, which is supposed to bind the long mycolate chains of TMM, exhibits slight differences. The conserved Leu152 in Ag85A and B is replaced by the bulky Phe150 in Ag85C, which in consequence leads to changes of surface topology in the mycolate binding portion (Fig. 5 ). The differences may alter substrate specificity and thus Ag85A, B and C might prefer different mycolic acids (Ronning et al., 2000; . smaller Leu230 in Ag85C is highlighted by an arrow. Also shown: Arginine 233, which covers the second carbohydrate binding pocket in Ag85C is replaced by smaller polar amino acids Thr235 and Ser235 in Ag85A and B, respectively. The surface is colored by electrostatic potential: The red and blue coloring represent negative and positive electrostatic potential, respectively. For Ag85A, B and C the coordinates from 1SFR, 1F0P and 1DQZ were used, respectively. The position of the trehalose molecules in Ag85A and Ag85C were modeled using the coordinates from 1F0P. The figure was prepared using GRASP (Nicholls et al., 1991) .
Ag85 as a putative drug target for tuberculosis treatment
The ongoing treatment battle of tuberculosis is worsened by the emergence of new strains of M. tuberculosis which are resistant to standard antibiotics. In the urgent need of new targets the biogenesis of fatty acids, mycolic acids and glycolipids stay as hotspots. There is hope that the crystal structure of antigen 85A, 85B and 85C shall help in rational drug development for TB (Ronning et al., 2000; .
The treatment by a trehalose analogue, 6-azido-6-deoxy-, ′-trehalose (ADT) inhibited the activity of all members of Ag85 complex in vitro and the growth of Mycobacterium aurum, and it also increased the efficacy of various antibiotics, supporting the importance of TDM (Belisle et al., 1997; Mizuguchi et al., 1983) . M. tuberculosis strain lacking Ag85C has a 40% decrease in the amount of cell wall linked mycolic acid, but with no change in the relative amounts of TMM and TDM (Jackson et al., 1999; Sanki et al., 2009a) . Furthermore, an Ag85A knockout strain lost the ability to grow in macrophage-like cell-lines and poor media which highlights the role of Ag85A in virulence and survival of the organism (Armitige et al., 2000) . In the last decades several antitubercular drugs have focused on targets in the mycobacterial cell wall . Most commonly, ethambutol targets the synthesis of arabinogalactan. Isoniazid and ethionamide inhibit biosynthesis of mycolic acids . Obviously, the crystal structure of antigen 85 complex is expected to accelerate the design of new drugs against Ag85 activity and cord factor biosynthesis ( Table 1) (Gobec et al., 2004; Sanki et al., 2009b; Wang et al., 2004) .
Drug development: Novel high-throughput screening assays for mycolytransferase 85A
Since the protein/substrate interactions and co-crystal structure of Ag85 are now known, the search for rapid assays for high-throughput screening (HTS) of large substance libraries has increased considerably. Most of the mycolyltransferase assays previously published are not suitable for HTS, due to their complexity or use of radioactive substances. The first one is a widely used radioassay which monitors enzymatic transfer of mycolic acids from a lipid-soluble TMM molecule to a radioactive water-soluble trehalose. Manipulation of the radioactive products in a two-phase reaction, extraction and thin layer chromatography allows visualization of the products (Kremer et al., 2002; Sathyamoorthy & Takayama, 1987) . Another test published uses the substrate analogue p-nitrophenyl-6-O-octanoyl-H-Dglucopyranoside that functions as the acyl donor but it may not represent the natural enzymatic activity (Boucau et al., 2009) . Also an excess of D-glucose is added to the reaction to function as an acyl acceptor and to promote turnover of the enzyme. Recently new assay for Ag85 was developed based on the use of mono and dihexanoyl trehalose substrates, followed by quantitation of the acyl-transfer to the unnatural trehalose by mass spectrometry (Backus et al., 2011) .
Synthesis step Enzyme Compound / class References FAS-I and FAS-II

KasA/KasB
Cerulenin (2R,3S-epoxy-4-oxo-7,10-trans,trans-dodecanoic acid amide (Schroeder et al., 2002) 
Mycolic acid biosynthesis
Unknown N-octanesulfonylacetamide (Parrish et al., 2001) 
Cyclopropanation
CMASs ( Methyl -D-arabinofuranoside (Sanki et al., 2009b) Ag85C 5-S-alkyl-5-thioarabinofuranoside analogues (Sanki et al., 2008) Ag85 complex Trehalose analogues (Wang et al., 2004 ) Ag85 complex ADT (6-azido-6-deoxy-, ′trehalose) (Belisle et al., 1997; Mizuguchi et al., 1983 ) Ag85 complex Phosphonate compounds (Gobec et al., 2004; Gobec et al., 2007 The mycobacterial glycolipids and TMM levels in the cell wall might give an indirect indication of the fitness of the cell inside the host cells specially in macrophages. Thus the quantitation of the mycobacterial TMM status after drug treatment may allow the estimation of drug effectiveness. Unfortunately, there is no method for measurement of the amount of glycolipids that is suitable for HTS. We designed an assay (Elamin et al., 2009 ) based on the use of natural substrate, and this mycolyltransferase assay offers a novel means to determine the TMM status of the mycobacterium cell wall and reflects the natural activity of mycolyltransferase enzyme based on simple steps. The new assay uses the natural substrate TMM, which can be easily purified from mycobacteria (Fujita et al., 2005) and reflects natural activity, allowing to get the most accurate kinetic parameters.
In the reaction Ag85A produces one molecule of trehalose as product per reaction cycle and by adding trehalase the trehalose converted to glucose, which can be easily measured (Fig. 6 ). Fig. 6 . Scheme for the new mycolyltransferase activity assay. Using trehalose that is produced as one of final products of mycolyltransferase reaction by trehalase to produce glucose, which is oxidized to gluconic acid and hydrogen peroxidase by glucose oxidase. Hydrogen peroxide reacts with o-dianisidine in the presence of peroxidase to produce a colored product (oxidized o-dianisidine), which will be converted to a stable colored product by sulfuric acid. The colored product is measured at 540 nm (Elamin et al., 2009 ).
Quantification of glucose is finally achieved by the glucose oxidase assay (Washko & Rice, 1961) . The amount of glucose is proportional to the TMM concentration. The assay showed that the antigen 85A can be assayed in the presence of methanol or mixture of chloroform/methanol, which is usually used to extract and purify the glycolipids from mycobacterium cell wall fractions. The results from substrate/solvent experiments showed that the enzyme activity was reduced in the presence of organic solvents than in standard buffer reaction alone. This indicates and proves that this method is useful to quantify the TMM from the total lipid of mycobacterium cells.
One molecule of trehalose produced from TMM processed by Ag85 complex, which by our method is converted to two molecules of glucose. We can calculate the original concentration of TMM and concentration of TDM and trehalose in the reaction by the following equations:
Concentration of [TMM] = concentration of [glucose]
(1) 
One has to keep in mind that the extracted total lipids contain free trehalose and glucose and will affect the final calculations. In this case and to calculate the TMM concentration in total lipids one should run different negative controls. The Z′ factor (Zhang et al., 1999) measurement of the current assay in different volumes indicates an excellent signal/noise (S/N) ratio for the assay and its high potential for HTS applications (Table 2) . 
Concluding remarks
Large gaps remain in our understanding of mycobacterium pathogenesis and persistence including the critical questions how bacteria survive in host cells and escape from the therapy. Future work on mycobacterial cell wall biosynthesis especially glycolipids and related pathways is expected to reveal in vivo drug-resistance mechanism. Perhaps more notably, the described new and low-cost colorimetric method based on use of TMM as natural substrate could brings flexibility and convenience in HT-screening of substance libraries and help in the development of novel drugs against tuberculosis. 
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